Metabolic and genomic analysis deciphering biocontrol potential of endophytic Streptomyces albus RC2 against crop pathogenic fungi.

Plant diseases caused by phytopathogenic fungi are one of the leading factors affecting crop loss. In the present study, sixty-one Streptomyces strains were screened for their antifungal activity against relevant wide range fungal pathogens prominent in Vietnam, namely Lasiodiplodia theobromae, Fusarium fujikuroi, and Scopulariopsis gossypii. Endophytic strain RC2 was the most effective strain in the mycelial inhibition of the tested fungi. Based on phenotypic characteristics, 16S rDNA gene analysis, and genomic analysis, strain RC2 belonged to Streptomyces albus. An ethyl acetate extract of S. albus RC2 led to the strong growth inhibition of S. gossypii Co1 and F. fujikuroi L3, but not L. theobromae N13. The crude extract also suppressed the spore germination of S. gossypii Co1 and F. fujikuroi L3 to 92.4 ± 3.2% and 87.4% ± 1.9%, respectively. In addition, the RC2 extract displayed potent and broad-spectrum antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and the phytopathogenic bacteria Ralstonia solanacearum and Xanthomonas oryzae. The genome of strain RC2 was sequenced and revealed the presence of 15 biosynthetic gene clusters (BGCs) with similarities ≥ 45% to reference BGCs available in the antiSMASH database. The UPLC-HRMS analysis led to the identification of 8 other secondary metabolites, which have not been reported in S. albus. The present study indicated that RC2 could be a potent biocontrol agent against phytopathogenic fungi. Further attention should be paid to antifungal metabolites without functional annotation, development of product prototypes, and greenhouse experiments to demonstrate effective control of the plant diseases.

Plant-derived bioactive compounds produced by Streptomyces variabilis LCP18 associated with Litsea cubeba (Lour.) Pers as potential target to combat human pathogenic bacteria and human cancer cell lines.

To date, endophytic actinomycetes have been well-documented as great producers of novel antibiotics and important pharmaceutical leads. The present study aimed to evaluate potent bioactivities of metabolites synthesized by the strain LCP18 residing in the Vietnamese medicinal plant Litsea cubeba (Lour.) Pers towards human pathogenic bacteria and human cancer cell lines. Endophytic actinomycete strain LCP18 showed considerable inhibition against seven bacterial pathogens and three human tumor cell lines and was identified as species Streptomyces variabilis. Strain S. variabilis LCP18 was phenotypically resistant to fosfomycin, trimethoprim-sulfamethoxazole, dalacin, cefoxitin, rifampicin, and fusidic acid and harbored the two antibiotic biosynthetic genes such as PKS-II and NRPS. Further purification and structural elucidation of metabolites from the LCP18 extract revealed five plant-derived bioactive compounds including isopcrunetin, genistein, daidzein, syringic acid, and daucosterol. Among those, isoprunetin, genistein, and daidzein exhibited antibacterial activity against Salmonella typhimurium ATCC 14,028 and methicillin-resistant Staphylococcus epidermidis ATCC 35,984 with the MIC values ranging from 16 to 128 µg/ml. These plant-derived compounds also exhibited cytotoxic effects against human lung cancer cell line A549 with IC50 values of less than 46 µM. These findings indicated that endophytic S. variabilis LCP18 can be an alternative producer of plant-derived compounds which significantly show potential applications in combating bacterial infections and inhibition against lung cancer cell lines.